R&D | April 20, 2026
NIT Rourkela develops novel bio-ink for 3D bioprinting and tissue engineering
The innovation is particularly suited for bone and cartilage repair
The innovation is particularly suited for bone and cartilage repair
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
Subscribe To Our Newsletter & Stay Updated
